55 results about "Gram-positive bacteria" patented technology

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The invention provides an application of GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection, and the GSK2018682 has a CAS number of 1034688-30-6. The invention also provides an application of the GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection. According to the technical scheme, the novel medical application of the GSK2018682 is disclosed, and the GSK2018682 has good antibacterial activity and anti-biofilm activity on various gram-positive bacteria and can inhibit growth of staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium and the like and formation of biofilms.

The present disclosure relates generally to Gram-positive bacterial strains having enhanced protein productivity phenotypes. Accordingly, certain aspects relate to compositions and methods for constructing recombinant (modified) Gram-positive bacterial strains for enhanced production of proteins of interest.

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for the treatment of infections caused by such microorganisms.

The bacterial strain Arasana bacillus (CECT 30655) belongs to Gram-positive bacterial flora and bacillus subtilis, and is a stimulant capable of stimulating adaptive metabolism of plants to resist water stress, an improving agent for plant yield and nutrition and an improving agent for polyphenol content. The strain is separated from rhizosphere soil of pinus coast, is cultured on a nutrient agar culture medium (PCA), and is identified as a new strain from the aspects of morphology, biochemistry and genetics for identification through whole genome sequencing. Under a water stress condition, the strain can enhance CO2 fixation and transpiration, optimize photosynthesis energy capture and reduce oxidative stress, so that the strain can be used for increasing yield; as a biological fertilizer, nutrient absorption can be promoted no matter whether water stress exists or not; and the content of antioxidant polyphenols in plant species with medicinal or edible values can also be improved, so that the fruit quality is improved.

The present disclosure provides method of whole genome sequencing of microorganisms such as Gram-positive bacteria, Gram-negative bacteria, viruses, and fungi. The various methods comprising steps of isolating nucleic acid from the microorganism and preparing a library of the isolated nucleic acid. Preferably, the methods of whole genome sequencing described herein are automated to provide a robust and efficient sequencing product for various utilities.

The invention belongs to the technical field of microbial prevention and control of plant diseases and insect pests, and particularly discloses a plant disease biocontrol bacillus cereus strain LCBC246 which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the strain is CGMCC No.33323. The invention further discloses a preparation method of the plant disease biocontrol bacillus cereus strain LCBC246. The LCBC246 strain provided by the invention is a gram-positive bacterium, has a very strong bacteriostatic effect on colletotrichum fucicola, the bacteriostatic rate is 92.1%, the disease control rate on the colletotrichum fucicola is 90.8%, and the LCBC246 strain has a very good inhibitory effect on other important plateau characteristic crop pathogenic bacteria and also has a remarkable crop growth promoting property. The bacterial inhibition rates of fermentation liquor and volatile substances of the strain LCBC246 on colletotrichum gloeosporioides of macadamia nuts are 62.70% and 76.58% respectively; the bacillus amyloliquefaciens can generate sterilization metabolites such as cellulase, amylase and siderophore, and has a very strong broad-spectrum bacteriostatic effect on various plant pathogenic fungi. Therefore, the strain LCBC246 and the metabolite thereof have the application value of developing bacterial biopesticides.

The invention discloses a bacillus amyloliquefaciens Jcc3 and application thereof in prevention and treatment of aquatic diseases, the classification name of the bacillus amyloliquefaciens Jcc3 is bacillus amyloliquefaciens, the bacillus amyloliquefaciens Jcc3 is preserved in China Center for Type Microbiological Culture Collection, the preservation time is January 25, 2024, and the preservation number is CCTCC NO: M 2024210. The bacillus amyloliquefaciens Jcc3 disclosed by the invention is identified as a gram positive bacterium. The strain can produce lipopeptides, proteins and other substances with bacteriostatic action, and has a significant inhibitory effect on aquatic disease aeromonas veronii. By inhibiting the growth and reproduction of the aeromonas veronii, aquatic diseases caused by the aeromonas veronii can be effectively prevented and controlled, so that the immunity of aquatic animals is enhanced, and the death rate of the aquatic animals is reduced. In conclusion, the bacillus amyloliquefaciens Jcc3 has great application potential in prevention and control of aquatic diseases, especially in prevention and control of diseases caused by aeromonas veronii.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 μg / mL to about 50 μg / mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm / kg to about 340 mOsm / kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.

Embodiments relate to a composition comprising a bacteriophage or a mutant thereof and a storage solution, wherein the bacteriophage or the mutant thereof is capable of killing a Gram-positive bacterium comprising Staphylococcus aureus, wherein the composition is stable for at least about a year at 39.2-46.4° F. (4-8° C.).

The invention discloses bacillus velezensis Jcl-10 and application of the bacillus velezensis Jcl-10 in prevention and treatment of vibrio cholerae. The strain Jcl-10 is preserved in the China Center for Type Culture Collection, the preservation time is January 25, 2024, and the preservation number is CCTCC N: M 2024212. The bacillus velezensis Jcl-10 disclosed by the invention is identified as a gram positive bacterium after being subjected to gram staining. The bacterial strain can produce antibacterial peptide substances, antibacterial protein substances, polyketide synthetase substances and the like with bacteriostatic action, and can be well applied to prevention and treatment of aquatic diseases caused by vibrio cholerae. The Jcl-10 is added into the aquatic feed, so that the morbidity of aquaculture animals can be effectively reduced, and the economic yield of the aquaculture animals can be increased. In conclusion, the bacillus velezensis Jcl-10 disclosed by the invention has outstanding performance in the prevention and treatment of vibrio cholerae, and provides a powerful guarantee for continuous and healthy culture of aquatic products.

The present invention belongs to the field of biomedical technologies, and specifically relates to antibacterial peptides derived from Myotis chinensis and their applications. The antibacterial peptides derived from Myotis chinensis are MC-CATH1, MC-CATH2 or MC-CATH3; the antibacterial peptides MC-CATH1, MC-CATH2, and MC-CATH3 derived from Myotis chinensis in the present invention have strong antibacterial activities against Gram-positive bacteria and Gram-negative bacteria, with a broad-spectrum and highly efficient antibacterial effect, and are characterized by low hemolytic activity, low cytotoxicity, high salt tolerance, and strong anti-bacterial biofilm activity. In addition, MC-CATH3 can kill bacteria by inducing an iron death-like mechanism in bacteria. MC-CATH1, MC-CATH2, and MC-CATH3 can be applied to the fields of medicine, cosmetics, food preservation, and aquaculture.

The photosensitive compound comprises a beta-lactam ring as shown in a formula I and a Ce6 photosensitizer, and does not contain a quenching group. When the compound is in contact with MRSA and other gram positive bacteria, the beta-lactam ring structure in the compound is combined with MRSA and other gram positive bacteria cell wall synthesis key enzyme-transpeptidase to provide targeting for the photosensitizer Ce6, so that the targeting effect on the bacteria is realized, the specificity is strong, a large amount of active oxygen is generated under illumination to kill the bacteria, and the compound can be used as a photosensitizer Ce6. Meanwhile, damage to normal tissues is avoided, photodynamic therapy on bacterial infection is facilitated, and the photodynamic therapy has high efficiency and low tissue toxicity.

The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and / or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

The invention provides a TB derivative with photodynamic antibacterial and anti-tumor activity and a synthesis method thereof, the derivative comprises a carbazole-TB-thiophene-pyridinium derivative, the structural formula of the derivative is shown in the specification, and the four derivatives have good viscosity response and aggregation-induced emission property and can efficiently and synchronously generate I-type and II-type active oxygen. The TB-CB-1, the TB-TPA-1 and the TB-TPA-2 have good photodynamic antibacterial activity on tested gram positive bacteria (G + bacteria), and the antibacterial rates of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 on the three kinds of G + bacteria are all larger than 90% when the concentration of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 is 2 mol. L <-1 >. The four compounds have strong photodynamic anti-tumor activity and large light and dark toxicity difference, the IC50 values of the TB-CB-1 to MCF-7, A549 and HepG2 cells are all greater than 100 [mu] g.mL <-1 > in the absence of illumination, and the IC50 values are respectively reduced to 1.53 [mu] g.mL <-1 > and 0.28 [mu] g.mL <-1 > under illumination; the IC50 of the TB-TPA-2 to A549 cells under a dark condition is greater than 200 [mu] g.mL <-1 >, and the illumination is reduced to 2.01 [mu] g.mL <-1 >. The invention provides a new thought for design and synthesis of a novel photodynamic antibacterial / antitumor photosensitizer.

The application discloses an antibacterial peptide ATMP7 mutant with improved bacteriostatic activity and application thereof. The application, on the basis of an amino acid sequence of a natural antibacterial peptide ATMP7, obtains antibacterial peptide mutants A7-M1, A7-M2, A7-M3, A7-M4, A7-M5, A7-M6 and A7-M7 with significantly improved bacteriostatic activity by combining an amino acid site-directed saturation mutation with a random mutation. The antibacterial peptide ATMP7 mutant provided by the application is convenient to artificially synthesize and low in cost, is significantly superior to the antibacterial peptide ATMP7 in bactericidal effect on gram-positive bacteria, has better stress resistance, has good heat resistance, can significantly reduce a feed-meat ratio of livestock and aquatic animals and improve growth performance indexes of the livestock and the aquatic animals in livestock and aquatic animal breeding, and provides a broader prospect for application of the antibacterial peptide product in the feed, food, medicine and other industries.

The present disclosure is generally related to Gram-positive bacterial strains comprising enhanced protein productivity phenotypes. Certain aspects are therefore related to compositions and methods for constructing recombinant (modified) Gram-positive bacterial strains for the enhanced production of proteins of interest.

The application provides a novel organic conjugated molecule, a long conjugated D-pi-A structure of which makes the organic conjugated molecule more likely to form a high positive charge density nanoparticle, and a large amount of active oxygen generated under white light irradiation can efficiently crack a bacterial cell membrane, and slow down the generation of bacterial drug resistance. The organic conjugated molecule shown in formula (I) has a strong photodynamic killing effect on gram-negative bacteria and gram-positive bacteria, has a low hemolysis rate, and has good biocompatibility. The application provides guidance for developing a high-efficiency and low-toxicity photodynamic antibacterial agent.

Provided herein is an antimicrobial composition for hygiene applications. The antimicrobial composition comprises an effective concentration of a cathelicidin LL-37 peptide fragment in combination with an effective concentration of non- ionic surfactant. The non-ionic surfactant is an Alkyl-Poly Glucoside (APG) or alcohol ethoxylates or both. The antimicrobial composition further comprises of a chelating agent like disodium EDTA, or malic acid or citric acid or GLDA or PES A. The composition achieves log reduction of at least 3 against Gram negative bacteria Pseudomonas aeruginosa, Escherichia coll and Gram positive bacteria Staphylococcus aureus, Enterococcus hirae.

The present invention discloses an antimicrobial peptide r-WRL derived from arthropod protein, its preparation method and application, and belongs to the field of bioengineering. The amino acid sequence of the antimicrobial peptide r-WRL is shown in SEQ ID No. 1. The present invention also discloses the application of the antimicrobial peptide r-WRL in the preparation of drugs for treating and / or preventing Gram-negative and / or Gram-positive bacterial infectious diseases. Since the antimicrobial peptide r-WRL exhibits a strong antibacterial effect, it can effectively inhibit Gram-negative and Gram-positive bacteria and has the potential for application in drugs for treating Gram-negative and Gram-positive bacterial infectious diseases. The antimicrobial peptide has low hemolytic activity and good physiological salt ion stability. In summary, the antimicrobial peptide r-WRL of the present invention has the development potential to become an antibiotic substitute.

The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 μg / mL to about 50 μg / mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm / kg to about 340 mOsm / kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.

The application discloses an alkyl pyridine salt type aggregation-induced emission compound, a preparation method and application thereof, a molecular structural formula of the alkyl pyridine salt type aggregation-induced emission compound is as follows: the preparation method comprises the following steps: stirring and refluxing raw material D, 1,4-dimethyl pyridine-1-iodide, anhydrous ethanol and piperidine overnight, after the reaction mixture is cooled, vacuum concentration is carried out, and the crude product is purified by elution, so that the alkyl pyridine salt type aggregation-induced emission compound is obtained. The alkyl pyridine salt type aggregation-induced emission compound provided by the application can simultaneously and efficiently kill gram-positive bacteria and gram-negative bacteria.

The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and / or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention is directed to an aqueous extract of Eruca sativa (arugula) leaves that has antimicrobial activity on Gram-positive bacteria and mycoplasmas. The extract may be purified away from solid or insoluble components, standardized based on the weight of its non-aqueous or solid content, assayed for antimicrobial activity, and provided in an aseptic or sterile form for pharmaceutical use. It may be used to kill or inhibit the growth of microorganisms such as Gram positive bacteria, promote wound healing, or as prophylaxis against host colonization or infection by a microorganism.

The invention relates to a soluble expression mussel mucin polypeptide and a preparation method and application thereof, the soluble expression mussel mucin polypeptide is at least one of MAP-PEP1 and MAP-PEP2, the amino acid sequence of the MAP-PEP1 is as shown in SEQ ID NO.1, and the amino acid sequence of the MAP-PEP2 is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the soluble expression mussel mucin polypeptide. The prepared mussel mucin polypeptides MAP-PEP1 and MAP-PEP2 rich in positive charges and DOPA groups can effectively destroy cell membranes of gram positive bacteria and gram negative bacteria, induce an oxidative stress reaction and inhibit bacterial proliferation; the material can be used for preparing a multifunctional biological active material, can also promote cell adhesion, migration and proliferation, is beneficial to wound healing, has a certain effect in the aspect of free radical scavenging, has great potential to become a next-generation multifunctional biological active material, and provides a theoretical basis for wide application in the fields of wound nursing, implant materials, drug delivery, cosmetics and the like.

The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase IIIC (DNA pol IIIC) enzyme to selectively reduce physiologically harmful Gram-positive bacteria with a genome having low amounts of Guanine and Cytosine (rather the genomes comprise a greater amount of adenine and thymine / uracil nucleotides) in the gut microbiome while simultaneously maintaining or increasing the proportions of beneficial microflora.

The application discloses an antibacterial peptide Ascaphin-5 modified body and application thereof, and belongs to the field of biological medicine. An artificial intelligent model independently developed by the application is used for modifying a natural antibacterial peptide Ascaphin-5, mutations are introduced into the amino acid sequence of the natural antibacterial peptide Ascaphin-5 at 8 positions, and modified bodies, antibacterial peptides Perceptide05 (GIKKWIKGWAKKLIKKVAKKIAKQ) and Perceptide07 (GIKKWIKGAIKKLIKKVAKWIWKQ) are obtained. The modified bodies, antibacterial peptides Perceptide05 and Perceptide07, can effectively improve the antibacterial activity of Ascaphin-5, the minimum inhibitory concentration value can be reduced by 64 times at most (i.e. the activity is improved by 64 times), and can simultaneously effectively inhibit gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration can reach 0.25 micromoles and 0.5 micromoles respectively, and can be used for development of a new generation of antibacterial drugs and antibacterial products.

The present invention relates to photoactive compounds and compositions comprising the same, and their use in the treatment and prevention of infections caused by Gram-positive bacteria. In embodiments, the present invention relates to methods of administering compounds and compositions, and particularly topical compositions, for the treatment and prevention of bacterial infections caused by Gram-positive bacteria, including diseases and conditions caused by Gram-positive bacteria, as well as infections of skin lesions.

The present invention relates to a compound of Formula (I): (I) or a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate, prodrug, polymorph, N-oxide, or bioisostere thereof; wherein: "R1, R2, and R3", "ring A", and "Het" are as defined in the specification, which can be used as a medicament or therapeutic agent in the prevention or treatment of a condition or a disease or a disorder where there is an advantage in inhibiting S. aureus or other Gram-positive bacteria.